Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Vomiting 1Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1Solitary Fibrous Tumors 1Solid Tumours 1Sarcoma 1Postoperative Nausea and Vomiting 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma 1Liposarcoma 1Leukemia, Hairy Cell 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Breast Carcinoma In Situ 1Adenocarcinoma, Mucinous 1

Interventions

Dexamethasone 808Bortezomib 446Lenalidomide 430Cyclophosphamide 336Melphalan 250Calcium Dobesilate 236daratumumab 217pomalidomide 201carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67Prednisone 64dexamethasone 21-phosphate 63isatuximab 62elotuzumab 60auricularum 57Antilymphocyte Serum 55belantamab mafodotin 54Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Famotidine × Clear all
NCT07101445 2026-02-10

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Emory University

Phase 4 Recruiting
94 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡